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A B S T R A C T
New designs of antimicrobial peptides are urgently needed in order to combat the threat posed by the recent
increase of resistance to antibiotics. In this paper, we present a new series of antimicrobial peptides, based on the
key structural features of the lantibiotic nisin. We have simplified the structure of nisin by conjugating the lipid
II-binding motif at the N-terminus of nisin to a series of cationic peptides and peptoids with known antibacterial
action and pore-forming properties. Hybrid peptides, where a hydrophilic PEG4 linker was used, showed good
antibacterial activity against Micrococcus luteus.
1. Introduction
The rise and spread of resistance to antibiotics and other anti-
microbials is well established as one of the greatest threats to modern
health. The last few years have seen a rise in bacterial infections that
are resistant to even last line of defence antibiotics such as vancomycin
and carbapenems. Thus, the bleak prospect of the occurrence of bac-
terial infections that are resistant to every available therapeutic may
soon become a reality.1 One of the tools that is essential to tackling
resistance is the discovery and development of new antimicrobials with
novel mechanisms of action. Several drug discovery initiatives have
been launched for the development of antibiotics, on both a national
and international level,1,2 but in spite of this the number of novel drugs
reaching the market each year is decreasing. The pressure for new
antibiotics is driving a resurgence of interest in natural products3 and
the re-evaluation of existing classes of compounds.1 Antimicrobial
peptides are one class of natural products that are seeing an increase in
interest from pharmaceutical research and development. Many peptides
are found to have potent antibacterial activity and a low propensity to
select for resistance but they are held back from clinical use by their
poor drug-like properties. New developments in peptide chemistry and
design are enabling the discovery of a new generation of peptide
therapeutics that can be selective, non-toxic and orally bioavailable.4
The lantibiotics are a group of antimicrobial peptides that have
received increasing attention over the last decade. They are ribosomally
synthesised by a wide range of bacteria and have notable structural
complexity, owing in part to the extensive range of post-translational
modifications that occur during the processing of the prepeptide. The
key structural feature of the lantibiotics is the incorporation one or
more of the uncommon amino acids, lanthionine (Lan) and methyl-
lanthionine (MeLan) (Fig. 1), which give rise to peptides with multiple,
often overlapping, cyclic motifs.5 A significant number of lantibiotics
are reported to have excellent antibacterial activity, notably against
multi-drug resistant strains of bacteria, but their development as drugs
has been held back by poor drug-likeness and a lack of synthetic
methods available to generate or modify their complex structures. The
poor drug-likeness of the lantibiotics can be attributed mostly to their
chemical instability: sulfur-containing lanthionine residues are prone to
oxidation; and unreacted dehydro residues can be easily cleaved in
basic conditions, attacked by nucleophiles or undergo hydrolysis in
strongly acidic conditions.6,7 Solubility can also be a problem; notably,
nisin is poorly soluble at neutral or high pH8 and whilst the thioether
bridges of lantibiotics provide some protection to proteolysis and
thermal degradation9 they are still prone to enzymatic degradation in
the gastrointestinal tract and in the bloodstream.10 Therefore the cur-
rent generation of lantibiotics are unlikely to be orally bioavailable.
However, as the pressure for new antimicrobials mounts, there are now
a small handful of lantibiotics undergoing clinical trials. For example,
NVB302 has completed Phase 1 clinical trials and MU1140 is in pre-
clinical development, both for treatment of C. difficile infections.11
Nisin is the most widely studied member of the lantibiotics (Fig. 1).
It has broad spectrum antimicrobial activity, notably against
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methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin
resistant enterococci (VRE). Despite widespread use as a food pre-
servative12 over a period of decades few nisin-resistant strains have
been reported (via mechanisms such as nisin-degrading enzymes and
modification of the cell wall13). It binds with high selectivity to lipid II,
a key biosynthetic precursor of the bacterial cell wall, with the resulting
8:4 nisin:lipid II complex leading to the formation of pores in the
bacterial membrane.14,15 NMR studies have revealed key interactions
between rings A and B of nisin and the pyrophosphate moiety of lipid
II.16 Although the nisin(1–12) fragment, which just comprises rings A
and B, has little or no antibacterial activity,17,18 it is able to antagonise
the activity of full-length nisin, suggesting that this fragment recognises
and maintains affinity for lipid II.17 After binding to lipid II, the C-
terminal moiety, nisin(23–33), comprising the DE rings, inserts into the
bacterial membrane to form the pore structure.19 The structural role of
ring C and the “hinge region” (nisin(20–22)) is not completely under-
stood, but are clearly important for the activity of nisin. Flexibility in
this region is one key factor. Mutagenesis studies have shown reduced
activity when Pro residues are introduced at positions 20 and 21;20
although binding to lipid II is still possible, the assembly and membrane
insertion of the nisin:lipid II pore complex is prevented by these mu-
tations.19 In support of this, screening of a library of mutants of all three
hinge positions identified sequences such as Ala-Ala-Ala and Ala-Ala-
Ser, with small, chiral amino acids, as leading to improved activity.21
Shorter hinge region mutants showed greatly reduced activity but
mutants with two extra amino acids were well tolerated,22 and muta-
tions in this region were also found to increase activity against sig-
nificant pathogens such as MRSA and VRE.23
The total synthesis of nisin using a segment synthesis approach24
and the solid-phase peptide synthesis of fragments and analogues of
nisin25–30 as well as of other lantibiotics31,32 has been reported.
Nevertheless, despite the many advances in synthetic methodology re-
ported over the past few decades33 neither synthetic methodology nor
bioengineering approaches have yet developed enough to enable the
rapid generation of analogues for antimicrobial screening34,35 although
a range of synthetic analogues of lantibiotics are providing insights into
the structural requirements for antibacterial activity and into the mode
of action.36 A semisynthetic approach to lantibiotic design and synth-
esis, using simpler and more accessible building blocks designed to
mimic the key functions of nisin (lipid II binding, flexible hinge and
membrane anchoring/pore formation) may be an effective alternative,
and may also afford lead structures with better chemical and enzymatic
stability, as well as improved pharmacokinetic properties. Several
groups have recently reported hybrid bioconjugates with the lipid II
binding motif of nisin modified with lipids,18 vancomycin,37 ma-
gainin,38 and a cross-stapled synthetic nisin D/E fragment,39 as well as
engineered nisin analogues with antimicrobial peptide sequences fused
to the lipid II binding motif.40 Most of these bioconjugates and en-
gineered analogues had slightly lower antibacterial action than wild
type nisin, with some losing the potential for pore formation.18,37,40
However, promising activities against Gram-negative bacteria,40 and
improved activities compared to nisin in clinically relevant resistant
bacteria18 have been reported. In this work, we aimed to prepare
simplified semisynthetic lantibiotics, where nisin(1–12) is conjugated
to known pore-forming peptides, mimicking the role of the complex
nisin D/E moiety. We have also investigated different synthetic linkers
between the pore-forming peptides and nisin(1–12), in order to eluci-
date whether the hinge region can be drastically simplified in this
manner, and whether hydrophobic or hydrophilic linkers are preferred.
2. Results and discussion
2.1. Design of nisin(1–12)-pore forming peptide hybrids
We aimed to prepare simplified semisynthetic lantibiotics, preser-
ving the activity and functionality of nisin, but with improved drug-like
properties and via an accessible synthetic route. By replacing the C-
terminal rings C, D and E, we removed many of the synthetically
challenging lanthionine residues and the unstable dehydro residues
(Fig. 2). One peptide/peptoid hybrid was also designed to minimize or
eliminate amino acid sequences that would be prone to enzymatic de-
gradation. The peptides were also designed with cationic sequences to
mimic the polarity of nisin and enhance aqueous solubility.
For the lipid II recognition moiety, we used the wild type nisin
(1–12) (A+B) 1, modified with an alkyne “handle” to allow rapid and
clean attachment to a spacer unit (mimicking the hinge region) and to
the pore forming peptide via click chemistry. As well as the mild and
biocompatible reaction conditions used for click chemistry, we also
envisaged that the resulting triazole moiety would be a good amide
bond mimic and would confer additional stability and resistance to
proteases on the resulting semisynthetic lantibiotic.41 As mimics of the
pore-forming region of nisin, we used two peptide sequences with well-
characterised antimicrobial and structural properties.
The mastoparan analogue Polybia-MP1 2 has been shown to have
antimicrobial activity against both Gram positive and Gram negative
bacteria,42 and the amphipathic α-helical structure has been demon-
strated to form pore structures, depending on the lipid bilayer com-
position.43 The cationic peptide Pexiganan 3 was developed through
Fig. 1. Structure of nisin Z, highlighting the residues involved in key aspects of the antimicrobial activity.
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structure-activity studies of magainin, a well-studied model anti-
microbial peptide. It has broad spectrum activity against both Gram
positive and Gram negative bacteria,44 and NMR studies have shown
that it adopts a dimeric antiparallel coiled coil structure on binding to
lipid bilayers45 and has the ability to form pores in a toroidal like
mechanism.46 In a bid to further minimize the protease susceptibility of
these semisynthetic lantibiotics, we also investigated a peptoid mimic47
of magainin (4) reported to have similar antibacterial activity to pex-
iganan.48 For the hinge mimics, we investigated the PEG linker 5, as
PEG is commonly incorporated into peptides to aid solubility, maintain
flexibility and reduce immunogenicity.49 Inspired by the good lipid II
binding activity of the recently reported nisin(1–12)-lipid conjugates,18
we also studied the effects of incorporation of the alkyl spacer 6 as a
hinge region substitute.
2.2. Preparation of nisin(1–12) (A+B) 1 for click chemistry
Nisin is susceptible to digestion at Lys(12) by trypsin,17 facilitating
the preparation of the wt lipid II binding moiety. Commercially avail-
able preparations typically contain 75% NaCl, 22.5% dairy proteins and
only 2.5% of nisin, however Liskamp and co-workers have recently
published reliable procedures for the scalable purification of nisin fol-
lowed by trypsin digestion to give nisin(1–12).50 Procedures for the
conversion of nisin fragments to propargyl amides for click chemistry
have also recently been reported.18,39,51 We therefore carried out the
enrichment, purification and trypsin digest as previously described50 to
afford nisin(1–12), which was then coupled to propargylamine to give
nisin(1–12) (A+B) 1 (Scheme 1).18
2.3. Synthesis of pore-forming peptides and peptoids with hydrophilic and
hydrophobic linkers
The tail peptide pexiganan 3 was synthesised via standard Fmoc
SPPS methodology, using Rink amide resin.52 Side-chain deprotection
and cleavage of the resin-bound intermediate 7 from the resin (Scheme
2) afforded the desired C-terminal amide peptide 3, which was used as a
control in subsequent biological experiments. To install the PEG hinge
mimic 5, commercially available Fmoc-NH-(PEG)4-COOH was coupled
to 7, followed by Fmoc-Lys(N3)-OH: deprotection and cleavage from the
resin then gave Lys(N3)-PEG4-pexiganan 8.
For the Polybia-MP1 based peptides, resin-bound intermediate 9
was also synthesised via standard Fmoc SPPS methodology. Cleavage
from the resin gave the desired Polybia-MP1 2 to be used as a control. A
similar synthetic sequence to that described above afforded Lys(N3)-
PEG4-Polybia-MP1 10 (Scheme 3). To install the hydrophobic linker,
11-azidoundecanoic acid 6 (prepared from the reaction of 11-bro-
moundecanoic acid with sodium azide) was coupled to 9, followed by
deprotection and cleavage from the resin, to give N3-C11-Polybia-MP1
11.
The peptoid mimic of magainin (4) was synthesised on Rink amide
resin via the previously reported procedure,53 using the amine mono-
mers (R)-(+)-α-methylbenzylamine (MBA) and N-Boc-1,4-butanedia-
mine (Scheme 4). Resin-bound intermediate 12 was also coupled to 11-
azidoundecanoic acid 6 to give N3-C11-peptoid 13.
2.4. Semisynthetic lantibiotics prepared via click chemistry
With the linker-peptide and linker-peptoid conjugates, and the nisin
(1–12) (A+B) 1 in hand, click chemistry was employed to form the
semisynthetic lantibiotics. Initially, copper-catalysed click chemistry
using conditions similar to those previously reported (2.4 equiv
CuSO4·5H2O and 4.8 equiv sodium ascorbate)37 was used to couple Lys
(N3)-PEG4-pexiganan 8 to nisin(1–12) (A+B) 1 to afford the semisyn-
thetic lantibiotic 14 (Table 1).
Whilst this procedure could also be used to conjugate N3-C11-
Polybia-MP1 11 to nisin(1–12) (A+B) 1 to give 16, in our hands this
approach proved capricious and the remaining peptides 15 and 17
could not be synthesised at all using this approach. However, an
Fig. 2. Modular design of simplified semisynthetic lantibiotics based on nisin.
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improved procedure utilizing addition of the polytriazole ligand tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA),17 previously re-
ported to improve copper-catalysed click reactions by stabilising the CuI
species,54 enabled all four of the semisynthetic lantibiotics to be suc-
cessfully synthesised (Scheme 5).
2.5. In vitro biological testing
In order to quantify the biological activity of the semisynthetic
lantibiotics, two in vitro screening methods, agar well diffusion and
growth inhibition in broth, were employed.55 In the initial round of
testing, the agar well diffusion method was used for the Polybia-MP1
hybrid peptides 15 and 16. Four different strains of bacteria were
tested, two indicator strains of Gram positive bacteria, Micrococcus lu-
teus and Bacillus subtilis and two strains of Gram negative bacteria, Es-
cherichia coli and Pseudomonas aeruginosa. A number of controls were
also used: kanamycin; Polybia-MP1 2; wild type nisin(1–12) (A+B) 1;
and full length nisin. Inhibition zones were visible for all hybrid pep-
tides and controls against M. luteus. All peptides performed worse
against the Gram-negative bacteria with only kanamycin showing any
inhibition against E. coli and P. aeruginosa. Whilst previous reports
suggested that pexiganan 344 and Polybia-MP1 242 would have sig-
nificant activity against both of these Gram-negative bacteria, in these
papers the microbiological testing was carried out using the broth di-
lution assay. We hypothesise that the agar well diffusion assay may not
be appropriate for peptides such as pexiganan and Polybia-MP1, as they
are rich in Lys residues which may bind to the agar and prevent in-
teractions with the bacteria.
To determine the MIC of the hybrid peptides and to compare their
activities more accurately, further testing was carried out on M. luteus
as this appeared to be the most sensitive strain of Gram positive bac-
teria. The broth micro-dilution method was used as this consumed the
minimum amount of material. Peptides (A+B)-Lys-PEG4-pexiganan 14,
(A+B)-Lys-PEG4-Polybia-MP1 15, (A+B)-C11-Polybia-MP1 16 and
(A+B)-C11-peptoid 17 were compared with wild-type nisin, nisin
(1–12) (A+B) 1, Polybia-MP1 2, Pexiganan 3 and peptoid 4 as controls
(Table 2, Figs. S1 and S2 (Supporting Information))
Nisin showed greater activity than any of the hybrids or linear
peptides. As expected, the nisin(1–12) (A+B) 1 showed very low ac-
tivity; poor activity against M. luteus and L. lactis,17 and also against B.
subtilis, S. aureus, MRSA and VRE18 have previously been reported. The
absence of antimicrobial activity for nisin(1–12) (A+B) 1 has been
attributed to the absence of the pore-forming C-terminal sequence. All
but one of the semisynthetic lantibiotics were shown to have greater
activity than nisin(1–12) (A+B) 1, although none performed sig-
nificantly better than their respective tail peptide controls 2, 3 and 4.
Clearly the conjugation of the pore-forming antibiotic peptides restores
antimicrobial activity to the lipid II binding motif. However, it does not
prove that the activity of these semisynthetic lantibiotics is conferred by
a lipid II dependent mechanism; their antibacterial properties may be
solely due to the activity of the cationic peptide moiety. Conversely, we
Scheme 1. Preparation of nisin(1–12) (A+B) 1. (i) H2O/CH2Cl2, centrifuga-
tion, filtration; (ii) trypsin, Tris buffer, 40 h (11%); (iii) propargylamine (51
equiv.), BOP, DIPEA, 20min (61%).
Scheme 2. Synthesis of pexiganan 3 and Lys(N3)-PEG4 pexiganan 8. (i) 96.5% TFA, 2.5% H2O, 1% TIPS; (ii) Fmoc-NH-PEG(4)-COOH, HBTU, DIPEA; (iii) piperidine,
DMF; (iv) Fmoc-Lys(N3)-OH, HBTU, DIPEA; (v) piperidine, DMF; (vi) 96.5% TFA, 2.5% H2O, 1% TIPS.
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cannot conclude that the activity of these semisynthetic lantibiotics is
due to pore formation: indeed, for the nisin(1–12)-lipid hybrids pre-
viously reported,18 experiments with model membranes ruled out pore
formation. Whilst the Lys-PEG4 linked peptides 14 and 15 showed
promising antimicrobial activity, the biological activities of the C11-
alkyl linked hybrids 16 and 17 were poor. This could be attributed to a
reduction of flexibility in the hinge region, or to disruption by the alkyl
linker of the helix-forming propensities of the Polybia-MP1 and peptoid
tails.
3. Conclusion
Lantibiotics hold considerable promise as leads from which the next
generation of antimicrobial therapeutics can be developed, due to their
unique mode of action. However, their poor drug-likeness and complex
structural features have hindered the realization of this potential. In this
paper, we report a new family of simplified semisynthetic lantibiotics.
These have been designed to be synthetically accessible, whilst retaining
the important features of the lantibiotic nisin – selective binding to lipid II
and pore formation – which lead to its biological activity. We have de-
veloped a simple approach involving bioconjugation of pore-forming he-
lical peptides to the key lipid II-binding region of nisin, the N-terminal
nisin(1–12) fragment, which can be used to rapidly access nisin analogues
without the need for complicated synthetic or biotransformation strate-
gies. This has established a methodology that could be used for synthesis
of libraries of peptides for screening for antimicrobial activity, in particular
against clinically relevant strains of MRSA and VRE. Cobb andMartin have
recently also reported a similar strategy to access other nisin(1–12)-pep-
toid hybrids. They have also observed increased activity compared with
truncated nisin(1–12) (A+B), with one bioconjugate having a MIC similar
to full-length nisin, although all had a reduction in activity compared to
the peptoids alone.56
Whilst it is surprising that these hybrid peptides and peptoids did
not result in a major improvement in biological activity, this suggests
that the structural requirements to bind lipid II and form a nisin
Scheme 3. Synthesis of Polybia-MP1 peptides. (i) 96.5% TFA, 2.5% H2O, 1% TIPS; (ii) Fmoc-NH-PEG(4)-COOH, HBTU, DIPEA; (iii) piperidine, DMF; (iv) Fmoc-Lys
(N3)-OH, HBTU, DIPEA; (v) 11-azidoundecanoic acid 6, HBTU, DIPEA.
Scheme 4. Synthesis of magainin related peptoids. (i) bromoacetic acid, DIC, NMP; (ii) (R)-(+)-MBA, NMP; (iii) 11-azidoundecanoic acid 6, HBTU, DIPEA; (iv)
96.5% TFA, 2.5% H2O, 1% TIPS. (Cycles of peptoid monomer synthesis are as follows: (a) bromoacetic acid, DIC, NMP, followed by either (b) (R)-(+)-MBA, NMP or
(c) Boc-1,4-butanediamine, NMP).
Table 1
Summary of click reactions to give semisynthetic lantibiotics 14–17.
Tail peptide Semisynthetic lantibiotic
Lys(N3)-PEG4-pexiganan 8 (A+B)-Lys-PEG4-pexiganan 14
Lys(N3)-PEG4-Polybia-MP1 10 (A+B)-Lys-PEG4-Polybia-MP1 15
N3-C11-Polybia-MP1 11 (A+B)-C11-Polybia-MP1 16
N3-C11-peptoid 13 (A+B)-C11-peptoid 17
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analogue:lipid II pore have been over-simplified. Indeed, the structure
of the linker between the lipid II-binding and pore forming regions, as a
mimic of the “hinge region” of nisin, is known to be critical19,20,21 and
recent high-resolution solid-state NMR studies of a lipid II-nisin com-
plex in DOPC liposomes has indicated the importance of this region for
the macromolecular organization of the pore.57 In this initial proof-of-
principle study, we have investigated the biological properties of hy-
drophilic Lys-PEG4 linked peptides and hydrophobic C11-alkyl linked
peptides. The Lys-PEG4 linked peptides had better activity, with the
best semisynthetic lantibiotic, (A+B)-Lys-PEG4-pexiganan 14,
matching the activity of its tail peptide, pexiganan 3. Moreover, the
resulting semisynthetic lantibiotics with PEG linkers have much better
aqueous solubility at physiological pH than wild type nisin, and are also
expected to have greater in vivo stability as they lack the amino acid
sequences that render nisin vulnerable to proteolysis.17 The mode of
action of these simplified semisynthetic lantibiotics still remains to be
established, and will be followed up by circular dichroism and model
membrane studies to elucidate the structure, lipid II binding and pore
formation properties of these peptides.
4. Experimental
4.1. General experimental details for chemical synthesis
Reagents were purchased from chemical suppliers and were used as
received without further purification. Dry DMF and THF were pur-
chased as anhydrous solvents in SureSeal bottles from Sigma-Aldrich
Co. Ltd. Brine refers to a saturated solution of sodium chloride in water
and sodium bicarbonate refers to a saturated solution of sodium hy-
drogen carbonate in water. Ether refers to diethyl ether and petrol to
petroleum ether fractions boiling between 40 and 60 °C. All water used
was either distilled using an Elga Purelab Option R7 water purifier or
used directly from a bottle of HPLC-grade water. All reactions were
carried out in closed systems under Argon.
LRMS refers to low resolution mass spectrometry and HRMS refers
to high resolution mass spectrometry. LRMS was performed on a Waters
Acquity UPLC attached to a Waters Acquity SQD using HPLC grade
water and acetonitrile (both with 0.1% formic acid) as the solvents.
HRMS Was performed on a Waters Xevo G2-XS QTof with ESI source
attached to a Waters Acquity UPLC system (I class).
1H NMR was performed on a 600MHz AMX Bruker Spectrometer.
The chemical shifts (δ) were given in units of ppm relative to tetra-
methylsilane (TMS), where δ(TMS)= 0 ppm. Data processing was car-
ried out using ACD/NMR Academic Edition, Advanced Chemistry De-
velopment, Inc. The multiplicity used for assignment is indicated by the
following abbreviations: s= singlet, d= doublet, t= triplet,
q= quadruplet, qn=quintet, m=multiplet, br= broad, app.
d.= apparent doublet and the coupling constants (J) were measured in
Hertz (Hz). Deuterated chloroform (CDCl3) was used as the solvent for
all NMR analysis.
4.2. General experimental details for peptide synthesis
Peptides were synthesised using an automated peptide synthesiser
in 5mL syringes with frits, purchased from Multisyntech GmbH.
Microwave couplings and click chemistry were carried out using a
Personal Chemistry Smith Creator Microwave Assisted Organic
Synthesizer loaded with either 0.5, 2 or 5mL reaction vials as
Scheme 5. Representative synthesis of semisynthetic lantibiotic (A+B)-Lys-PEG4-pexiganan 14. (i) CuSO4·5H2O (2.4 equiv), sodium ascorbate (4.8 equiv), TBTA
(0.6 equiv), μW, 80 °C, 20min.
Table 2
MICs determined by broth micro-dilution.
Peptide MIC (μM)
Nisin 0.0234
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purchased from Biotage. HPLC grade DMF purchased from Sigma
Aldrich was used as the primary solvent throughout peptide synthesis.
Peptides were centrifuged using an Eppendorf Centrifuge 5810 R and
were lyophilised using an VirTis Benchtop Pro freeze dryer. Fmoc-
protected amino acids were purchased from Novabiochem, except for
Fmoc-NH-PEG(4)-COOH which was purchased from Iris Biotech Gmbh.
4.3. Methods for automated peptide synthesis
Peptides were synthesised on a MultiSynTech Syro Peptide
Synthesiser (model MP-60). The peptide synthesiser contains an agita-
tion block which held 5mL syringes with frits connected to a vacuum
pump to remove solvents. Pre-loaded Rink amide resins (100–200
mesh) and Fmoc protected amino acids were purchased from Merck
KGaA/Novabiochem, and were used in all cases of automated peptide
synthesis. The total volume of all reagents in each step was 1.5mL and
all reagents were dissolved in HPLC grade DMF.
Fmoc deprotection: A solution of piperidine in DMF (40% v/v,
1.5 mL) was added to the syringe containing an N-terminal Fmoc-pro-
tected peptide. The mixture was agitated for 20 s every minute for a
total of 3min. The reagents were removed by vacuum filtration and the
resin was washed with DMF (6×1.5mL). A second portion of piper-
idine in DMF (40% v/v, 0.75mL) was added to the syringe followed by
DMF (0.75mL) to give a final solution of 20% v/v of piperidine in DMF.
The mixture was agitated for 20 s every minute for a total of 10min.
The reagents were removed by vacuum filtration and the resin washed
with DMF (6× 1.5mL).
Amino acid coupling: Fmoc protected amino acid (4 eq.), HBTU
(4 eq.) and DIPEA (10 eq.) were added to the reaction syringe. The
mixture was agitated for 20 s every minute for a total of 40min. The
reagents were removed by vacuum filtration and the resin was washed
with DMF (4× 1.5mL).
4.4. Methods for automated peptoid synthesis
Peptoids were synthesised in a similar manner to peptides using an
automated peptide synthesiser as before. In addition to DMF, reagent
grade N-methylpyrrolidone (NMP) purchased from Sigma Aldrich was
also used as a solvent. The synthesiser was reprogrammed to add the
non-amino acid reagents and both NMP and DMF were used as solvents.
Bromoacetic acid was used as a 1.2M solution in DMF and Boc-buta-
nediamine and (R)-(+)-α-methylbenzylamine (MBA) were both used as
1M solutions in NMP. N,N′-Diisopropylcarbodiimide (DIC) was used
neat.
Fmoc deprotection of resin: The Fmoc deprotection protocol for au-
tomated peptide synthesis was used.
Bromoacetic acid coupling: Bromoacetic acid (20 eq.) and DIC
(25 eq.) were added to the reaction syringe and the mixture was agi-
tated for 20 s every minute for a total of 1 h. The reagents were removed
by vacuum filtration and the resin was washed with DMF (3×1.5mL)
and NMP (3× 1.5mL).
Amine coupling: The required amine (25 eq.) was added to the re-
action syringe and the mixture was agitated for 20 s every minute for a
total of 1 h. The reagents were removed by vacuum filtration and the
resin was washed with NMP (3×1.5mL) and DMF (3×1.5mL).
4.5. Peptide cleavage and purification
Cleavage and purification procedures were the same for both pep-
tides and peptoids.
Cleavage from the resin: Peptides and peptoids were washed with DMF
(5×1.5mL), CH2Cl2 (5×1.5mL), methanol (5×1.5mL) and diethyl
ether (5×1.5mL) and dried in desiccator for 30min. A solution of 96.5%
TFA, 2.5% water and 1% TIPS (1mL) was added to the reaction syringe
and the mixture was agitated for 40min on the platform shaker. The
cleavage solution was removed by filtration and the filtrate was
transferred to a 15mL Falcon tube containing 13mL of diethyl ether to
give a milky white precipitate. Another aliquot (1mL) of the cleavage
solution was added to the reaction syringe and the mixture was agitated
for a further 20min on the platform shaker. The cleavage solution was
again removed by filtration and transferred to the same Falcon tube. The
Falcon tube was centrifuged for 10min at 4000 rpm at 0 °C after which the
diethyl ether was carefully decanted. This process was repeated with a
further 2 aliquots of fresh diethyl ether (13mL) after which the peptide
was re-dissolved in water and lyophilised.
HPLC purification: Peptides and peptoids were analysed and purified
via reverse phase HPLC using a Dionex system with a PDA-100 pho-
todiode array detector, a model ASI-100 automated sample injector and
Chromeleon Software version 2.0. Preparative purification was per-
formed using an ACE 5 C8-300 column (150× 10mm), a Dr Maisch
Reprosil Gold 200 C8 (150×10mm) or a Phenomenex Onyx mono-
lithic C18 column (100× 3mm) with UV detection at 214 and 254 nm.
Conditions varied between peptides and are reported as such. The
mobile phase is quoted as a percentage of solvent B (acetonitrile with
0.1% TFA) in solvent A (water with 0.1% TFA). The fractions con-
taining the correct peak were combined and lyophilised.
4.6. Peptide analysis by HPLC
Purified peptides were analysed using a using the same Dionex
system as used for purification. An ACE 5 C18-AR analytical column
(150× 4.6mm) was used with a flow rate of 1.0 mLmin−1 and a linear
gradient of 5–95% over 60min (A=water, 0.1% TFA and
B=acetonitrile, 0.1% TFA) and with UV detection at 214 and 254 nm
unless otherwise stated.
4.7. Peptide and peptoid synthesis
Pexiganan resin-bound intermediate 7: Rink amide resin (50mg,
0.7 mmol g−1) was added to a reaction syringe, washed with DMF
(4×1.5mL) and left to swell for 20min in 1.5mL DMF. After this time,
the Fmoc group was removed using the standard Fmoc deprotection
step as described in Section 4.3. Subsequent amino acid couplings and
Fmoc deprotections were carried out as described in Section 4.3 with
stock solutions of the following amino acids: Fmoc-Ala-OH; Fmoc-Phe-
OH; Fmoc-Gly-OH; Fmoc-Ile-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH;
Fmoc-Val-OH.
Pexiganan 3: Pexiganan resin-bound intermediate 7 was cleaved
under standard conditions, washed with ether and lyophilised as de-
scribed above. The peptide was purified using a gradient of 5–40% over
30min at 4mLmin−1 using a C18 semi-preparative column. The re-
sidue was purified a second time using the same conditions to give
pexiganan 3 (8.7 mg, 7%).
LRMS: (ES+) calculated [C122H210N32O22]+=2475.6292; found
m/z=360.7 [M+6H+K]7+, 413.7 [M+6H]6+, 420.4 [M+5H
+K]6+, 496.2 [M+5H]5+, 620.2 [M+4H]4+, 826.6 [M+3H]3+.
Lys(N3)-PEG4-pexiganan 8: Fmoc-NH-PEG(4)-COOH was coupled to
pexiganan resin-bound intermediate 7 using standard amino acid cou-
pling protocol as described in Section 4.3. Fmoc deprotection was
carried out as described above. Fmoc-Lys(N3)-OH was then coupled to
the N-terminus using the standard amino acid coupling protocol and
Fmoc deprotection was carried out as described in Section 4.3. The
peptide was cleaved under standard conditions, washed with ether and
lyophilised as described above. The peptide was purified using a gra-
dient of 5–40% over 30min at 4mLmin−1 using a C18 semi-pre-
parative column. The residue was purified a second time using the same
conditions to give Lys(N3)-PEG4-pexiganan 8 (10.0mg, 5%).
HRMS: (ES+) calculated [C139H242N37O28]+=2877.8645; found:
m/z=480.6530 [M+6H]6+, 576.5814 [M+5H]5+, 720.4740 [M
+4H]4+.
Polybia-MP1 resin-bound intermediate 9: Rink amide resin (50mg,
0.7 mmol g−1) was added to a reaction syringe, washed with DMF
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(4× 1.5mL) and left to swell for 20min in 1.5mL DMF. After this time,
the Fmoc group was removed using the standard Fmoc deprotection
step as described in Section 4.3. Subsequent amino acid couplings and
Fmoc deprotections were carried out as described above with stock
solutions of the following amino acids: Fmoc-Ala-OH; Fmoc-Asp(OtBu)-
OH; Fmoc-Gln-OH; Fmoc-Ile-OH; Fmoc-Lys(Boc)-OH; Fmoc-Leu-OH;
Fmoc-Trp-OH. Double coupling was used for all amino acid couplings.
Polybia-MP1 2: Polybia-MP1 resin-bound intermediate 9 was
cleaved under standard conditions, washed with ether and lyophilised
as described in Section 4.5. The peptide was purified using a gradient of
5–40% over 30min at 4mLmin−1 using a C18 semi-preparative
column. The residue was purified a second time using the same con-
ditions to give Polybia-MP1 2 (4.1mg, 5% yield).
LRMS: (ES+) [C78H133N20O19]+ calculated= 1654.0050; found m/
z=424.9 [M+2Na+2H]4+, 552.2 [M+3H]3+, 828.2 [M+2H]2+.
Lys(N3)-PEG4-Polybia-MP1 10: Fmoc-NH-PEG(4)-COOH was cou-
pled to Polybia-MP1 resin-bound intermediate 9 using standard amino
acid coupling protocol as described in Section 4.3. Fmoc deprotection
was carried out as described above. Fmoc-Lys(N3)-OH was then coupled
to the N-terminus using the standard amino acid coupling protocol and
Fmoc deprotection was carried out as described above. The peptide was
cleaved under standard conditions, washed with ether and lyophilised
as described in Section 4.5. The peptide was purified using a gradient of
5–40% over 30min at 4mLmin−1 using a C18 semi-preparative
column. The residue was purified a second time using the same con-
ditions to give Lys(N3)-PEG4-Polybia-MP1 10 (6.0mg, 7%).
HRMS: (ES+) [C95H163N25O25]+ calculated= 2055.2325; found:
m/z=514.8204 [M+4H]4, 686.0886 [M+3H]3+, 1028.6212 [M
+2H]2+.
N3-C11-Polybia-MP1 11: 11-azidoundecanoic acid 6 was coupled to
Polybia-MP1 resin-bound intermediate 9 using standard amino acid
coupling protocol as described in Section 4.3. Fmoc deprotection was
carried out as described above. The peptide was cleaved under standard
conditions, washed with ether and lyophilised as described in Section
4.5. The peptide was purified using a gradient of 5–40% over 30min at
4mLmin−1 using a C18 semi-preparative column. The residue was
purified a second time using the same conditions to give N3-C11-
Polybia-MP1 11 (6.0mg, 8%).
HRMS: (ES+) [C89H152N23O20]+ calculated=1863.1579; found m/
z=622.0614 [M+3]3+, 932.5844 [M+2H]2+.
Peptoid mimic resin-bound intermediate 12: Rink amide resin (50mg,
0.7 mmol g−1) was added to a reaction syringe, washed with DMF
(4× 1.5mL) and left to swell for 20min in 1.5mL DMF. After this time,
the Fmoc group was removed using the standard Fmoc deprotection
step as described in Section 4.4 above. The resin bound amine was then
bromoacetylated with the addition of 1.2M bromoacetic acid in DMF
(584 µL) and neat DIC (135 µL) and the coupling was carried out as
described above. Bromide substitution was then carried out with the
addition of 1M MBA (875 µL) and the coupling was carried out as de-
scribed above. These two reactions were repeated followed by a third
bromoacetylation and the addition of 1M N-Boc butanediamine in NMP
(891 µL). The coupling was carried out as described above. The peptoid
chain was built up using this submonomer approach with stock solu-
tions of the reagents as listed below:
Reagent Mass (g) Solvent Volume (mL)
Bromoacetic acid 1.67 DMF 10.0
DIC 2.04 neat 2.50
N-Boc-butanediamine 0.941 NMP 5.00
MBA 1.21 NMP 10.0
Peptoid mimic 4: Peptoid mimic resin-bound intermediate 12 was
cleaved under standard conditions, washed with ether and lyophilised
as described in Section 4.5. The peptide was purified using a gradient of
5–60% over 30min at 5mLmin−1 using a C18 semi-preparative
column. The peptoid was purified a second time using the same con-
ditions to give 4 (4.1mg, 5% yield).
LRMS: (ES+) [C104H140N17O12]+ calculated=1819.0862; found
m/z=455.5 [M+4H]4+, 607.2 [M+3H]3+.
N3-C11-peptoid 13: 11-azidoundecanoic acid 7 was coupled to
Peptoid mimic resin-bound intermediate 12 using standard amino acid
coupling protocol as described in Section 4.3. The peptoid was cleaved
under standard conditions, washed with ether and lyophilised as de-
scribed in Section 4.5. The peptoid was purified using a gradient of
5–60% over 30min at 5mLmin−1 using a C18 semi-preparative
column. The peptoid was purified a second time using the same con-
ditions to give N3-C11-peptoid 13 (6.5mg, 7%).
HRMS: (ES+) [C115H159N20O13]+ calculated= 2028.2390; found
m/z=508.0722 [M+4H]4+, 677.0892 [M+3H]3+, 1015.1232 [M
+2H]2+.
4.8. Semisynthetic lantibiotics prepared via click chemistry
(A+B)-Lys-PEG4-pexiganan 14: Nisin(1–12) (A+B) 1 (1.00mg,
710 nmol) dissolved in 50 µL of DMF and Lys(N3)-PEG4-pexiganan 8
(2.8mg, 710 nmol) dissolved in 50 µL of water were transferred to a
250 µL microwave vial. Stock solutions of CuSO4·5H2O (42.0 mg,
5.00mL water), sodium ascorbate (67.0mg, 5.00mL water) and tris[(1-
benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA) (2.20mg, 500 µL
DMF) were made up. 50.0 µL of each stock solution was added to the
reaction vial. The reaction mixture was then irradiated for 20min at
80 °C. After this time, the reaction mixture was quenched with buffer
(3mL, 0.1% TFA in water), filtered and purified directly using reverse
phase HPLC over a gradient of 5–40% over 30min at 4mLmin−1 using
a C18 semi-preparative column. The peptide was purified a second time
using the same conditions to give (A+B)-Lys-PEG4-pexiganan 14
(300 µg, 8% yield).
HRMS: (ES+) [C193H328N51O40S2]+ calculated= 4064.4636; found
m/z=581.7919 [M+7H]7+, 678.5875 [M+6H]6+, 814.1019 [M
+5H]5+, 1017.3734 [M+4H]4+.
(A+B)-Lys-PEG4-Polybia-MP1 15: Nisin(1–12) (A+B) 1 (1.00mg,
710 nmol) dissolved in 50 µL of DMF and Lys(N3)-PEG4-Polybia-MP1
10 (2.37mg, 710 nmol) dissolved in 50 µL of water were transferred to
a 250 µL microwave vial. Stock solutions of CuSO4·5H2O (42.0 mg,
5.00mL water), sodium ascorbate (67.0mg, 5.00mL water) and TBTA
(2.20mg, 500 µL DMF) were made up. 50.0 µL of each stock solution
was added to the reaction vial. The reaction mixture was then irra-
diated for 20min at 80 °C. After this time, the reaction mixture was
quenched with buffer (3mL, 0.1% TFA in water), filtered and purified
directly using reverse phase HPLC over a gradient of 5–40% over
30min at 4mLmin−1 using a C18 semi-preparative column. The pep-
tide was purified a second time using the same conditions to give
(A+B)-Lys-PEG4-Polybia-MP1 15 (300 µg, 9% yield).
HRMS: (ES+) [C149H250N39O37S2]+ calculated= 3241.8316; found
m/z=649.3778, 811.7181 [M+4H]4+, 1081.5 [M+3H]3+.
(A+B)-C11-Polybia-MP1 16: Nisin(1–12) (A+B) 1 (1.00mg,
710 nmol) dissolved in 50 µL of DMF and N3-C11-Polybia-MP1 11
(1.57mg, 710 nmol) dissolved in 50 µL of water were transferred to a
250 µL microwave vial. Stock solutions of CuSO4·5H2O (42.0 mg,
5.00mL water), sodium ascorbate (67.0mg, 5.00mL water) and TBTA
(2.20mg, 500 µL DMF) were made up. 50.0 µL of each stock solution
were added to the reaction vial. The reaction mixture was then irra-
diated for 20min at 80 °C. After this time, the reaction mixture was
quenched with buffer (3mL, 0.1% TFA in water), filtered and purified
directly using reverse phase HPLC over a gradient of 5–50% over
40min at 5mLmin−1 using a C18 semi-preparative column. The pep-
tide was purified a second time to give (A+B)-C11-Polybia-MP1 16
(200 µg, 8% yield).
HRMS: (ES+) [C143H238N37O32S2]+ calculated= 3049.7570; found
m/z=610.9606 [M+5H]4+, 763.4 [M+4H]4+, 1017.5 [M+3H]3+.
(A+B)-C11-peptoid 17: Nisin(1–12) (A+B) 1 (1.00mg, 710 nmol)
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dissolved in 50 µL of DMF and N3-C11-peptoid 13 (1.76mg, 710 nmol)
dissolved in 50 µL of water were transferred to a 250 µL microwave vial.
Stock solutions of CuSO4·5H2O (42.0mg, 5.00mL water), sodium as-
corbate (67.0 mg, 5.00mL water) and TBTA (2.20mg, 500 µL DMF)
were made up. 50.0 µL of each stock solution were added to the reac-
tion vial. The reaction mixture was then irradiated for 20min at 80 °C.
After this time, the reaction mixture was quenched with buffer (3mL,
0.1% TFA in water), filtered and purified directly using reverse phase
HPLC over a gradient of 5–60% over 30min at 5mLmin−1 using a C18
semi-preparative column. The peptide was purified a second time using
the same conditions to give (A+B)-C11-peptoid 17 (250 µg, 9% yield).
HRMS: (ES+) [C169H245N34O25S2]+ calculated=3214.8381; found
m/z=536.9815 [M+6H]6+, 644.1757 [M+5H]5+, 804.9666 [M
+4H]4+, 1072.9497 [M+3H]4+.
4.9. In vitro screening
General methods: In vitro work was carried out under sterile condi-
tions in a category 2 safety hood. Oxoid Nutrient Broth No 2 was used
purchased from ThermoFisher Scientific as a dehydrated powder and
was made up as a solution according to the manufacturer’s instructions.
OD600 readings of bacteria stock solutions were taken using a
Nanodrop 2000c Spectrophotometer. Polypropylene and polystyrene
96-well plates were purchased from Greiner Bio One. Aeraseal Sterile
gas permeable seals were purchased from Excel Scientific. 96-well
plates were incubated overnight in Eppendorf Thermomixer comfort/C
incubators. OD625 readings of 96-well plates were measured using a
Tecan infinite M200 Pro plate reader with i-control 1.11 software.
All of the peptides and peptoids synthesised were cleaved in TFA
and purified using a solvent system with 0.1% TFA. It was assumed that
all of the cationic residues exist as TFA salts. Due to the high number of
cationic residues, the TFA content makes up a significant proportion of
the isolated mass. It has previously been reported that the presence of
TFA can inhibit bacterial growth in assays58 so to check if it would have
an effect in the assays, a control solution of sodium acetate TFA salt was
tested for antibacterial activity. It was made up to the same con-
centration as the sample with the highest concentration of TFA salt. No
inhibitory activity was observed in agar well diffusion plates at the
maximum amount tested, 25 µL of 0.4mgmL−1.
Agar well diffusion method screening: All compounds to be tested
were made up to a concentration of 1 mgmL−1 in sterile water ex-
cept sodium trifluoroacetate which was made up to 0.4 mg mL−1. LB
agar plates were inoculated with 100 µL of an overnight culture of
either Micrococcus luteus, Bacillus subtilis, Escherichia coli or
Pseudomonas aeruginosa and spread evenly across the surface of the
plate. The overnight cultures of bacteria were grown at 37 °C in
Oxoid Nutrient Broth No. 2 with shaking. Four wells of 8 mm dia-
meter were punched into each plate. 25 µL of the stock solution was
spotted into a well for each strain of bacteria. Plates were incubated
for 48 h at 37 °C except for those inoculated with M. luteus which
were incubated at 30 °C. Later work with M. luteus was carried out at
37 °C. After 48 h, antibacterial activity was evaluated by the ap-
pearance of a zone of growth inhibition.
Broth micro-dilution method screening: Oxoid Nutrient Broth No 2 was
used with 1% DMSO to aid solubilisation. All compounds to be tested
were made up to 0.60mM stock solutions in sterile water with 1%
DMSO. To ensure peptides were fully dissolved stock solutions were
placed in a bath sonicator for 30 s. 10 µL of peptide stock solution was
added to 90 µL of nutrient broth with 1% DMSO. This was then trans-
ferred to the first column of a 96-well polypropylene plate. A two-fold
serial dilution was carried out as described by R. Hancock and co-
workers:59 50 µL of nutrient broth was added to columns 2–10. 50 µL
was taken from column 1 and added to column 2 and mixed well by
pipetting up and down 8 times. 50 µL was taken from column 2 and
added to column 3 and again mixed well. This process was repeated
through to column 10. The 50 µL taken from 10 was discarded. 250 µL
of nutrient broth was added to the sterility control column, 12, and
240 µL was added to the growth control column, 11.
10 µL of an overnight stock of bacteria adjusted to have an OD 0.817
(of a 1 in 10 dilution) was added to each well except from the final
column which was reserved as a sterility control containing only nu-
trient broth. A further portion of Oxoid Nutrient Broth No 2 was added
to make each well up to 250 µL total volume. A gas permeable adhesive
seal was applied to each plate and they were incubated for 20 h at 37 °C.
After this time broth and bacteria were re-suspended and transferred to
clear, flat-bottomed, polystyrene 96-well plates and the OD was mea-
sured. The MIC is defined as the lowest concentration of the anti-
microbial agent that inhibits visible growth of the tested isolate as
observed with the unaided eye. The error of the MIC results is estimated
as one half of the interval between the MIC dilution and the next lowest
concentration (i.e. the highest concentration that resulted in growth of
bacteria).
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